|Bid||40.45 x 1400|
|Ask||40.46 x 4000|
|Day's range||40.38 - 40.55|
|52-week range||33.26 - 42.40|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||14.07|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||2.12 (5.62%)|
|Ex-dividend date||18 Feb 2021|
|1y target est||47.27|
Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.
AZD7442 failed to meet the main goal of stopping people developing symptomatic COVID-19 but did offer some hope that it could help people who had not yet come into contact with the virus.
Shares of iTeos Therapeutics (NASDAQ: ITOS) surged 37% on Monday after it reached an agreement with GlaxoSmithKline (NYSE: GSK) to co-develop an experimental cancer treatment known as EOS-448. EOS-448 is a monoclonal antibody treatment for patients with cancer. GlaxoSmithKline also intends to begin new combination studies of EOS-448 with some of its other immuno-oncology therapies next year.